Literature DB >> 22043959

Vaccination of travelers: how far have we come and where are we going?

Lin H Chen1, David R Hill, Annelies Wilder-Smith.   

Abstract

Vaccine recommendations are a prominent part of health preparations before international travel. We review progress made in the past decade regarding vaccines used primarily by persons traveling from high-income countries to low- and middle-income countries. The combined hepatitis A-B vaccine, the recently licensed Vero cell-derived Japanese encephalitis vaccine and conjugated quadrivalent meningococcal vaccines are discussed. This article provides updates on yellow fever vaccine-associated visceral and neurologic adverse events, indications for influenza vaccine in travelers, the rapid immunization schedule for tick-borne encephalitis vaccine, schedules for postexposure rabies prophylaxis, and new insights about oral cholera vaccines following the outbreak in Haiti. The future should bring vaccines for serogroup B Neiserria meningitidis, dengue and malaria, as well as an inactivated yellow fever vaccine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22043959     DOI: 10.1586/erv.11.138

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  4 in total

Review 1.  Prospects for dengue vaccines for travelers.

Authors:  Sl-Ki Lim; Yong Seok Lee; Suk Namkung; Jacqueline K Lim; In-Kyu Yoon
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

Review 2.  An overview of travel-associated central nervous system infectious diseases: risk assessment, general considerations and future directions.

Authors:  Morteza Izadi; Arman Is'haqi; Mohammad Ali Is'haqi; Nematollah Jonaidi Jafari; Fatemeh Rahamaty; Abdolali Banki
Journal:  Asian Pac J Trop Biomed       Date:  2014-08

3.  Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States.

Authors:  Peng-Jun Lu; Kathy K Byrd; Trudy V Murphy
Journal:  Vaccine       Date:  2013-03-21       Impact factor: 3.641

4.  Hepatitis B vaccination coverage among adults aged ≥ 18 years traveling to a country of high or intermediate endemicity, United States, 2015.

Authors:  Peng-Jun Lu; Alissa C O'Halloran; Walter W Williams; Noele P Nelson
Journal:  Vaccine       Date:  2018-03-28       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.